Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. The company is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. The company is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
Follow-Up Questions
What is Baudax Bio Inc (BXRXQ)'s P/E Ratio?
The P/E ratio of Baudax Bio Inc is 0
Who is the CEO of Baudax Bio Inc?
Ms. Geraldine Henwood is the President of Baudax Bio Inc, joining the firm since 2019.
What is the price performance of BXRXQ stock?
The current price of BXRXQ is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Baudax Bio Inc?
Baudax Bio Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Baudax Bio Inc market cap?
Baudax Bio Inc's current market cap is $43.589999999999996
